Intravoxel incoherent motion (IVIM) modeling of diffusion MRI during chemoradiation predicts therapeutic response in IDH wildtype glioblastoma.
Diffusion MRI
Glioblastoma
Intravoxel incoherent motion imaging
Progression-free Survival
Radiotherapy
Survival
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
03
09
2020
revised:
14
12
2020
accepted:
22
12
2020
pubmed:
9
1
2021
medline:
24
4
2021
entrez:
8
1
2021
Statut:
ppublish
Résumé
Prediction of early progression in glioblastoma may provide an opportunity to personalize treatment. Simplified intravoxel incoherent motion (IVIM) MRI offers quantitative estimates of diffusion and perfusion metrics. We investigated whether these metrics, during chemoradiation, could predict treatment outcome. 38 patients with newly diagnosed IDH-wildtype glioblastoma undergoing 6-week/30-fraction chemoradiation had standardized post-operative MRIs at baseline (radiation planning), and at the 10th and 20th fractions. Non-overlapping T1-enhancing (T1C) and non-enhancing T2-FLAIR hyperintense regions were independently segmented. Apparent diffusion coefficient (ADC Higher ADC ADC
Sections du résumé
BACKGROUND
Prediction of early progression in glioblastoma may provide an opportunity to personalize treatment. Simplified intravoxel incoherent motion (IVIM) MRI offers quantitative estimates of diffusion and perfusion metrics. We investigated whether these metrics, during chemoradiation, could predict treatment outcome.
METHODS
38 patients with newly diagnosed IDH-wildtype glioblastoma undergoing 6-week/30-fraction chemoradiation had standardized post-operative MRIs at baseline (radiation planning), and at the 10th and 20th fractions. Non-overlapping T1-enhancing (T1C) and non-enhancing T2-FLAIR hyperintense regions were independently segmented. Apparent diffusion coefficient (ADC
RESULTS
Higher ADC
CONCLUSION
ADC
Identifiants
pubmed: 33418005
pii: S0167-8140(20)31264-0
doi: 10.1016/j.radonc.2020.12.037
pmc: PMC8186561
mid: NIHMS1708695
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
258-265Subventions
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Radiology. 2012 Dec;265(3):874-81
pubmed: 23074258
Neuro Oncol. 2011 May;13(5):546-57
pubmed: 21297128
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16759-64
pubmed: 16267128
Sci Rep. 2014 Dec 01;4:7208
pubmed: 25434593
J Neurosurg. 2011 Jul;115(1):3-8
pubmed: 21417701
Magn Reson Med. 1992 Sep;27(1):171-8
pubmed: 1435202
IEEE Trans Med Imaging. 2010 Jan;29(1):196-205
pubmed: 19923044
J Clin Oncol. 2008 Jul 10;26(20):3387-94
pubmed: 18541899
Tomography. 2019 Mar;5(1):7-14
pubmed: 30854437
AJR Am J Roentgenol. 2000 Aug;175(2):425-30
pubmed: 10915688
Neuro Oncol. 2015 Sep;17(9):1188-98
pubmed: 26250565
Biomed Res Int. 2015;2015:234245
pubmed: 25945328
J Magn Reson Imaging. 2016 Sep;44(3):620-32
pubmed: 26880230
Cancer Cell. 2010 May 18;17(5):510-22
pubmed: 20399149
AJNR Am J Neuroradiol. 2002 Feb;23(2):194-9
pubmed: 11847041
J Neurooncol. 2018 Apr;137(2):313-319
pubmed: 29383647
Cancer. 2008 Jul 15;113(2):405-10
pubmed: 18484594
Neuroradiology. 2013 Oct;55(10):1189-96
pubmed: 23852430
Neuro Oncol. 2004 Jul;6(3):227-35
pubmed: 15279715
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
J Neurooncol. 2015 May;122(3):497-505
pubmed: 25773062
J Neurooncol. 2015 May;123(1):179-88
pubmed: 25894597
Radiology. 2010 Feb;254(2):564-76
pubmed: 20093527
J Neurooncol. 2015 Jan;121(2):331-9
pubmed: 25351579
Magn Reson Imaging. 2020 Apr;67:69-78
pubmed: 31891760
Radiology. 2016 Jan;278(1):13-32
pubmed: 26690990
MAGMA. 2018 Apr;31(2):269-283
pubmed: 29075909
Clin Neuroradiol. 2017 Dec;27(4):485-492
pubmed: 27116215
AJNR Am J Neuroradiol. 2016 Dec;37(12):2251-2257
pubmed: 27561834
J Magn Reson Imaging. 2014 Mar;39(3):624-32
pubmed: 24068649
AJNR Am J Neuroradiol. 2011 Dec;32(11):1978-85
pubmed: 21393407
Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5524-9
pubmed: 15805192
Cancer Res. 2009 Jul 1;69(13):5296-300
pubmed: 19549889
Acta Radiol. 2001 Mar;42(2):123-8
pubmed: 11281143
Radiology. 2017 Jan;282(1):212-221
pubmed: 27428890
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Radiother Oncol. 2020 Mar;144:121-126
pubmed: 31805516
AJNR Am J Neuroradiol. 2014 Feb;35(2):256-62
pubmed: 23928134
Radiology. 1988 Aug;168(2):497-505
pubmed: 3393671
Acta Neurol Scand. 2010 Sep;122(3):159-67
pubmed: 20298491
PLoS One. 2016 Jul 07;11(7):e0158887
pubmed: 27387822
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Neuroimage. 2019 Feb 15;187:56-67
pubmed: 29277647